The invention relates to the use of derivatives of cyclopentenone for the inhibition or prevention of the growth or multiplication of cancer cells, and to therapeutic compositions containing such compounds. The invention relates more specifically to the use of derivatives of cyclopentenone for the inhibition and/or prevention of cancer of the colon, pancreas, larynx, ovary, duodenum, kidney, oral cavity, prostate, lung, endothelial cells and leukemias
[EN] CYCLOPENTENONE DERIVATIVES FOR CANCER THERAPY<br/>[FR] DERIVES DE CYCLOPENTENONE UTILISES POUR TRAITER DES CANCERS
申请人:DABUR RES FOUNDATION
公开号:WO2004056738A1
公开(公告)日:2004-07-08
The invention relates to the use of derivatives of cyclopentenone for the inhibition or prevention of the growth or multiplication of cancer cells, and to therapeutic compositions containing such compounds. The invention relates more specifically to the use of derivatives of cyclopentenone for the inhibition and/or prevention of cancer of the colon, pancreas, larynx, ovary, duodenum, kidney, oral cavity, prostate, lung, endothelial cells and leukemias.
PDE4 inhibition is achieved by novel compounds, e.g., N-substituted diarylamine analogs. The compounds of the present invention are of Formulas I-III:
wherein A, B, D, E, G, J, K, R
1
, R
2
, R
3
, R
4
, R
11
, R
12
, R
13
, R
14
, R
21
, R
22
, R
23
and R
24
are as defined herein.
PDE4 inhibition is achieved by novel compounds, e.g., N-substituted diarylamine analogs. The compounds of the present invention are of Formulas I-III:
wherein A, B, D, E, G, J, K, R
1
, R
2
, R
3
, R
4
, R
11
, R
12
, R
13
, R
14
, R
21
, R
22
, R
23
and R
24
are as defined herein.